Email Updates

Search form

You are here

7 July 2017 VOLUME 18 ISSUE 27

Media Coverage

  • Speaking at Fortune’s Brainstorm Health conference, Intarcia CEO Kurt Graves argued that administering medicine via pills and injections works for short-term illnesses, but those with chronic conditions often forget or tire of taking their medication, so an implant could be the perfect solution.

    July 7, 2017
  • “We are entering a make-or-break point that will determine whether we end HIV and TB or whether the epidemics will be prolonged indefinitely,” said Connie Kganakga, acting chief executive of the South African National Aids she unveiled an updated plan last month. But the latest version of the NSP is in trouble.

    July 7, 2017
    Financial Times
  • The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the US Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.

    July 6, 2017
    The Body
  • The AIDS Research Center of the Thai Red Cross Society has revealed that its PREP program has successfully helped prevent mother-to-child transmission of HIV.

    July 6, 2017
    Pattaya Mail
  • Scientists from The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) may have found the best delivery mode for a vaccine against HIV.

    July 6, 2017
  • Georgia’s public health commissioner, an OB-GYN and two-time Republican candidate for Congress, has been named the next director of the CDC. Dr. Brenda Fitzgerald will replace Dr. Tom Frieden, who served as CDC director for eight years before stepping down in January.

    July 6, 2017
  • Remember the days when the antiretroviral medicine that saved the lives of people living with HIV ....was provided to the people who needed it only in countries that could afford it? That past, when lines between life and death followed the lines of a map, would be prologue for countries around the world under the terms of a Trump administration plan for the US President’s Emergency Plan for AIDS Relief to “continue to work towards epidemic control” in just 12 countries.

    July 6, 2017
    Science Speaks
  • Talking to the ATQ crew about all things PrEP is Matthew Bacon, the outreach officer for gay and bi men at the WA AIDS Council.

    July 5, 2017
  • The Executive Director of UNAIDS, Michel Sidibé, emphasized the importance of cities in ending the AIDS epidemic by 2030 during a speech to the Council of Paris on 4 July, highlighting that cities can use their HIV responses as a transformative force for society.

    July 4, 2017
  • The FDA recently accepted a Biologics License Application for TaiMed Biologics’ investigational monoclonal antibody ibalizumab, being developed as a potential new treatment for multidrug-resistant HIV....Ibalizumab was granted priority review with a Prescription Drug User Free Act action date of January 3, 2018....If approved, it will be the first ART with a new mechanism of action in almost 10 years and the only treatment that does not need to be taken daily.

    July 3, 2017
  • The untimely death of Babatunde Osotimehin, Executive Director of UNFPA, comes at a turbulent time for sexual and reproductive health and rights....As Ann Starrs said in his obituary..., his experience as a physician and health minister in a conservative society led him to put evidence and data, health and rights, at the forefront of his thinking, leading the UNFPA in foregrounding sexual and reproductive health and rights in the global agenda, even when—perhaps especially when—this generated opposition.

    July 1, 2017
  • Lawmakers have yet to release spending bills covering the NIH — which accounts for about half of all civilian basic research dollars — CDC, and EPA....Most observers expect current spending levels to be extended well into the 2018 year, which begins 1 October, before Congress reaches final agreement. That means researchers may have a long wait before they learn the fate of their favorite federal funding source.

    June 30, 2017
  • On 21 June, the European Court of Justice issued a ruling in the case of a French man who claimed his multiple sclerosis was triggered by a hepatitis vaccine....Some argue that rather than dealing a blow against science or vaccines, the court sought to balance individuals' rights against society's interest in preventing disease; others say the ruling leaves a worrying amount of room for judges in the EU to ignore certain kinds of scientific evidence.

    June 30, 2017
  • President Trump has nominated Jerome M. Adams, MD, MPH, who has advocated for needle exchange programs, to be the next US Surgeon General. Adams served as Indiana State Health Commissioner since 2014 and held the position when then-Indiana Gov. Mike Pence, now US vice president, authorized a needle exchange program to stop an HIV and hepatitis C outbreak...primarily linked to IV drug use of opioids.

    June 30, 2017
  • The recent resignation of six members of a presidential HIV/AIDS advisory board just months after the inauguration of President Donald J. Trump reflected a distrust of the new administration’s ability to handle the epidemic and a view that it does not take the issue seriously, according to former members.

    June 29, 2017
  • ‘NHS England and Public Health England announced in December 2016 that up to £10 million is to be made available to run a three-year trial for pre-exposure prophylaxis to answer outstanding questions about future access and implementation,’ said Health Minister Steve Brine. ‘Work continues to ensure a robust trial starting as quickly as possible.’

    June 28, 2017
    Gay Star News
  • In 2007, DC residents were diagnosed with HIV at a rate of nearly four per day. That rate dropped to less than one resident per day in 2016. The 74 percent decline in new cases — from 1,333 in 2007 to 347 in 2016 — can be attributed to factors that include a needle-exchange program, condom distribution and increasing use of preventive medication to halt the spread of the disease, city officials said.

    June 27, 2017
    Washington Post
  • Despite the availability of effective ART, disseminated Mycobacterium avium complex, or DMAC, is still a mortal danger to patients with HIV/AIDS. DMAC, a late-stage complication of HIV, also disproportionately affects minorities and is the result of delayed and inconsistent treatment, [researchers] wrote in Open Forum Infectious Diseases.

    June 27, 2017
  • One in five people living with HIV in a European study reported a decline in everyday functioning as a result of cognitive problems such as memory loss, difficulties in solving problems, poor concentration or reduced attention span, researchers from the CIPHER study group report in the Journal of Acquired Immune Deficiency Syndromes. But people who reported these problems were also more likely to have comorbid conditions...and ought to be assessed for these problems first.

    June 19, 2017
  • Four factors are associated with neurocognitive decline in people living with HIV with an undetectable viral load, investigators from Canada report in the Journal of Acquired Immune Deficiency Syndromes. The strongest individual risk factor was impaired kidney function. People with all four risk factors had a 95% risk of neurocognitive decline over three years, compared to a 2% risk for people with no risk factors.

    June 16, 2017

Published Research